EUVIMEDEUVIMED entdecken
Crossref

Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer

Qian Chen, Jie Sun, Sisi Ling, Hongchao Yang iD, Tuanwei Li, Xiaohu Yang, Meng Li, Mingming Du, Yejun Zhang, Chunyan Li, Qiangbin Wang iD

ACS Nano · 04.03.2025 · 19 (8) · 8212-8226

DOI: 10.1021/acsnano.4c17899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 24.02.2025. Verfasst von Qian Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Su…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Lung Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cells have shown unparalleled efficacy in treating hematologic cancers, but their application in solid tumor treatment remains challenging due to the immunosuppressive tumor microenvironment (TME). It is highly significant to develop safe and efficient TME regulatory strategies for the adoptive cellular immunotherapy of tumors. Herein, a TME-responsive nanoimmunomodulator (FMANAC) is designed using a multicomponent coordination self-assembly method to reconstruct the immune chemokine gradient and overcome the suppression of CAR-T cell immunoactivity, thereby improving the infiltration and killing efficiency of CAR-T cells within tumors. The acidic TME induces the disassembly of FMANAC, followed by the drug release, in which C-C chemokine ligand 5 (CCL5) improves the disrupted chemotactic gradient within tumors, increasing CAR-T cell recruitment and infiltration into deep tissue; and NLG919 reverses indoleamine 2,3-dioxygenase (IDO)-mediated immunosuppression in TME to create a favorable environment for CAR-T cells to exert their killing function. In the H460 lung cancer animal model, this nanoregulatory strategy combined with engineered CD276 CAR-T cells, guided by multiplexed near-infrared-II fluorescence imaging for programmed administration, achieved significantly enhanced tumor treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentLung NeoplasmsReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesNanoparticlesAnimalsHumansMiceCell Line, Tumor

Stichwörter der Autor:innen

CAR-T cellsNIR-II fluorescence imagingimmunotherapylung cancertumor microenvironment

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Scien…
  • The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou 215008, China.
  • Department of Orthopedics, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou 215031, China.
  • College of Materials Sciences and Optoelectronic Technology, University of Chinese Academy of Sciences, Beijing 100049, China.
  • School of Physical Science and Technology, ShanghaiTech University, Shanghai 201210, China.

ORCID-Profile: Hongchao Yang, Qiangbin Wang

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China
  • Science and Technology Program of Suzhou
  • Chinese Academy of Sciences

Zitieren

APA

Chen, Q., Sun, J., Ling, S., Yang, H., Li, T., Yang, X., Li, M., Du, M., Zhang, Y., Li, C., & Wang, Q. (2025). Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer. ACS Nano, 19(8), 8212-8226. https://doi.org/10.1021/acsnano.4c17899

Vancouver

Chen Q, Sun J, Ling S, Yang H, Li T, Yang X, et al. Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer. ACS Nano. 2025;19(8):8212-8226. doi:10.1021/acsnano.4c17899

BibTeX
@article{Chen2025,
  author = {Chen, Qian and Sun, Jie and Ling, Sisi and Yang, Hongchao and Li, Tuanwei and Yang, Xiaohu and Li, Meng and Du, Mingming and Zhang, Yejun and Li, Chunyan and Wang, Qiangbin},
  title = {Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer},
  journal = {ACS Nano},
  year = {2025},
  volume = {19},
  number = {8},
  pages = {8212--8226},
  doi = {10.1021/acsnano.4c17899}
}
Kostenlos starten →